Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Momenta (MNTA) upgraded to Overweight from Neutral at JPMorgan with analyst Eric Joseph saying the company on Monday detailed early clinical results from its Phase 1/2 study of M254 in immune thrombocytopenic purpura and the data, albeit early, support "compelling activity / relative potency" compared with conventional intravenous immunoglobulin. He believes the ITP data, or five of six patients achieving platelet response by standard criteria, give "real clinical credence to the disruptive potential" of M254. 2. Oaktree Specialty Lending (OCSL) upgraded to Overweight from Equal Weight at Wells Fargo with analyst Finian O'Shea saying that while he made the ratings change based on valuation, he continues to view Business Development Companies positively given a benign credit environment and meaningful spread to short end benchmark rates. 3. PG&E (PCG) upgraded to Buy from Neutral at Citi with analyst Praful Mehta saying the company's potential agreement with bondholders is a "big step forward." 4. Maxar Technologies (MAXR) upgraded to Neutral from Underperform at Credit Suisse with analyst Robert Spingarn saying he thinks the recently-announced MDA sale significantly de-risks the Maxar story by meaningfully reducing the likelihood of a liquidity crunch. 5. PetroChina (PTR) upgraded to Neutral from Underperform at Credit Suisse. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.